Pharmaceuticals

With a new chair from Genmab and a board of industry titans, BioNJ is poised to bolster New Jersey's status as a global biotech powerhouse.

CRB appoints veteran John R. Lupa, Jr. to spearhead national construction, a strategic move to dominate the booming life sciences and food facility market.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

With promising new data for its cancer and obesity pipeline, Corbus Pharmaceuticals prepares for a crucial investor presentation at the Oppenheimer conference.

Compugen adds strategic powerhouse Dr. Michele Holcomb to its board, a move signaling its ambition to convert AI-driven discoveries into market value.

A new drug, JIN-A02, shows early promise in overcoming resistance to common lung cancer therapies, even shrinking hard-to-treat brain metastases.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

A potential first therapy for Charcot-Marie-Tooth disease heads to a major conference, showing promising functional gains despite missing its primary goal.

New data reveals Mesoblast's cell therapy Ryoncil dramatically boosts survival in GvHD patients when used early, paving the way for a major adult trial.

As Caroline Dorsa retires, Biogen elects Dr. Maria Freire as its new chair, a strategic move placing deep scientific expertise at the helm for a critical period.

Life sciences consulting firm Trinity lands #7 in Vault's prestigious rankings, signaling a major shift toward technology-enabled commercialization.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

Wesley Pharmaceuticals launches a 503B-compliant NAD+ injection, promising quality in the booming anti-aging market amid scientific debate over its efficacy.

A new collaboration with Datavant will securely connect real-world health data, aiming to speed up research and deliver life-saving therapies faster.

A new partnership with Uniphar will use managed access programs to provide the lymphoma therapy LYMPHIR to European patients with limited treatment options.

NervGen Pharma to unveil data showing its drug NVG-291 provides lasting functional gains for chronic spinal cord injury, a major step forward.

With key leadership promotions, AscellaHealth aims to streamline the complex path from drug discovery to patient delivery for life sciences companies worldwide.

Pharma veteran Pinder Sahota joins digital health firm Reset Health, signaling a strategic shift to integrated care in the new era of weight-loss drugs.

South Korea's Hugel shatters sales records with a 105% surge in the Americas, signaling a major power shift in the global medical aesthetics market.